Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma

Philipp Sergeev, Sadiksha Adhikari, Juho J. Miettinen, Maiju-Emilia Huppunen, Minna Suvela, Ana Slipicevic, Nina N. Nupponen, Klara Acs, Fredrik Lehmann, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 6000–6001.

https://doi.org/10.1182/blood-2022-162182

Published: 2022

Journal Articles

Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma

Kim Anh Giang, Mizuha Kanaya, Thorstein Boxaspen, Minoru Kanaya, Silje Zandstra Krokeide, Yumei Diao, Fredrik Schjesvold, Fredrik Lehmann, Johan Nilvebrant, Stefan Svensson Gelius, Karl-Johan Malmberg, Per-Åke Nygren

Blood (2022) 140 (Supplement 1): 10699–10700.

https://doi.org/10.1182/blood-2022-164753

Published: 2022

Journal Articles

The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies

Juho J. Miettinen, Tanja Ruokoranta, Vilma Ikonen, Maiju-Emilia Huppunen, Klara Acs, Fredrik Lehmann, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 10697–10698.

https://doi.org/10.1182/blood-2022-166090

Published: 2022

Journal Articles

Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma

Philipp Sergeev, Sadiksha Adhikari, Juho J. Miettinen, Maiju-Emilia Huppunen, Minna Suvela, Ana Slipicevic, Nina N. Nupponen, Fredrik Lehmann, Caroline A. Heckman

Blood (2021) 138 (Supplement 1): 1194.

https://doi.org/10.1182/blood-2021-147191

Published: 2021

Journal Articles

Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity

Arghya Ray, Ting DU, Nina N. Nupponen, Fredrik Lehmann, Jakob Lindberg, Joachim Gullbo, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2021-153705

Published: 2021

Journal Articles

Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells

Konstantin Byrgazov, PhD, Annica Rasmusson, Claes Andersson, Malin Berglund, Lena Lenhammar, Håkan Melhus, Joachim Gullbo, Ana Slipicevic, Fredrik Lehmann, Rolf Larsson, Thomas Lind, Mårten Fryknäs

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-136749

Published: 2020

Journal Articles

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Beau M Idler, Olivia Perez De Acha, MD, Owen Lockerbie, PhD, Ken Flanagan, PhD, Fredrik Lehmann, MSc, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Daniel W. Sherbenou, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138762

Published: 2020

Journal Articles

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Konstantin Byrgazov, PhD, Marianne Kraus, Andrej Besse, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, MD, Lenka Besse

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136725

Published: 2020

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

Journal Articles

AKN-028, a FLT-3 Kinase Inhibitor In Preclinical Development, Induces Significant Gene Regulation That Differs From PKC-412

Vendela C Parrow, PhD, Anna Eriksson, Dr, Hanna Göransson, Linda Rickardson, Fredrik Lehmann, PhD, Lena Lenhammar, Rolf Larsson, Prof, Martin Hoglund, MD, PhD

Blood (2010) 116 (21): 1837.

https://doi.org/10.1182/blood.V116.21.1837.1837

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma

Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma

The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies

Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma

Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity

Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

AKN-028, a FLT-3 Kinase Inhibitor In Preclinical Development, Induces Significant Gene Regulation That Differs From PKC-412

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only